Changfa Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Changfa Xia has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Wanqing Chen
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
29 shared publications Hongmei Zeng
National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
15 shared publicationsRongshou Zheng
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
14 shared publicationsZhixun Yang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
13 shared publicationsSiwei Zhang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12 shared publicationsHe Li
Changfa Xia, PhD, Office of Cancer Screening, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; He Li, PhD, Office of National Cancer Regional Medical Centre in Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, China; and Wanqing Chen, MD, PhD, Office of Cancer Screening, National Cancer Centre/National Clinical Research Centre for...
11 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Wiley in Advanced Science
- p. e78077
Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study
The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high‐throughput nanoparticle‐enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine‐metabolite signature combined with alpha‐fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early‐stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD + /SIRT1‐dependent mechanism that increases HIF1α stability and activates glycolytic and MAPK signaling. Overall, we developed a promising metabolic diagnostic signature for LC and identified NAM‐associated metabolic signaling as a potential contributor to LC progression.
- 4 October 2026
- Published by Wiley in Advanced Science
- p. e78077
Open AccessMetabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study
The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high‐throughput nanoparticle‐enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine‐metabolite signature combined with alpha‐fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early‐stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD + /SIRT1‐dependent mechanism that increases HIF1α stability and activates glycolytic and MAPK signaling. Overall, we developed a promising metabolic diagnostic signature for LC and identified NAM‐associated metabolic signaling as a potential contributor to LC progression.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (28) , 3376-3378
Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (28) , 3376-3378
Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy
- Top Cited PapersOpen Access
- 7 August 2024
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 21 (8) , 1-12
Global, regional, and national burden of early-onset gastric cancer
Objective: The burden of gastric cancer (GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017. Methods: The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates (ASIRs) were evaluated using cancer registry data from volumes X–XII of the Cancer Incidence in Five Continents (CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate (ASMR) and the Human Development Index (HDI). Results: There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008–2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females. Conclusions: GC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.
- 7 August 2024
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 21 (8) , 1-12
Top Cited PapersOpen AccessGlobal, regional, and national burden of early-onset gastric cancer
Objective: The burden of gastric cancer (GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017. Methods: The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates (ASIRs) were evaluated using cancer registry data from volumes X–XII of the Cancer Incidence in Five Continents (CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate (ASMR) and the Human Development Index (HDI). Results: There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008–2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females. Conclusions: GC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.
- 7 May 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (7) , 1203-1211
The current infection with Helicobacter pylori and association with upper gastrointestinal lesions and risk of upper gastrointestinal cancer: Insights from multicenter population‐based cohort study
The relationship between Helicobacter pylori (H. pylori) infection and upper gastrointestinal (UGI) cancers is complex. This multicenter, population‐based cohort study conducted in seven areas in China aimed to assess the correlation between current H. pylori infection and the severity of UGI lesions, as well as its association with the risk of gastric cancer (GC) and esophageal cancer (EC). From 2015 to 2017, 27,085 participants (aged 40–69) completed a standardized questionnaire, and underwent a 13C‐urea breath test. Then a subset underwent UGI endoscopy to assess the UGI lesion detection rates. All individuals were followed up until December 2021 to calculate the hazard ratios (HRs) for UGI cancers. H. pylori infection prevalence was 45.9%, and among endoscopy participants, 22.2% had gastric lesions, 19.2% had esophageal lesions. Higher detection rates of gastric lesions were noted in the H. pylori‐positive population across all lesion severity levels. Over a median follow‐up of 6.3 years, 104 EC and 179 GC cases were observed, including 103 non‐cardia gastric cancer (NCGC) cases and 76 cardia gastric cancer (CGC) cases. H. pylori‐infected individuals exhibited a 1.78‐fold increased risk of GC (HR 1.78, 95% confidence interval [CI] 1.32–2.40) but no significant increase in EC risk (HR 1.07, 95% CI 0.73–1.57). Notably, there was a higher risk for both NCGC and CGC in H. pylori‐infected individuals. This population‐based cohort study provides valuable evidence supporting the association between current H. pylori infection and the risk of both NCGC and CGC. These findings contribute to the empirical basis for risk stratification and recommendations for UGI cancer screening.
- 7 May 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (7) , 1203-1211
The current infection with Helicobacter pylori and association with upper gastrointestinal lesions and risk of upper gastrointestinal cancer: Insights from multicenter population‐based cohort study
The relationship between Helicobacter pylori (H. pylori) infection and upper gastrointestinal (UGI) cancers is complex. This multicenter, population‐based cohort study conducted in seven areas in China aimed to assess the correlation between current H. pylori infection and the severity of UGI lesions, as well as its association with the risk of gastric cancer (GC) and esophageal cancer (EC). From 2015 to 2017, 27,085 participants (aged 40–69) completed a standardized questionnaire, and underwent a 13C‐urea breath test. Then a subset underwent UGI endoscopy to assess the UGI lesion detection rates. All individuals were followed up until December 2021 to calculate the hazard ratios (HRs) for UGI cancers. H. pylori infection prevalence was 45.9%, and among endoscopy participants, 22.2% had gastric lesions, 19.2% had esophageal lesions. Higher detection rates of gastric lesions were noted in the H. pylori‐positive population across all lesion severity levels. Over a median follow‐up of 6.3 years, 104 EC and 179 GC cases were observed, including 103 non‐cardia gastric cancer (NCGC) cases and 76 cardia gastric cancer (CGC) cases. H. pylori‐infected individuals exhibited a 1.78‐fold increased risk of GC (HR 1.78, 95% confidence interval [CI] 1.32–2.40) but no significant increase in EC risk (HR 1.07, 95% CI 0.73–1.57). Notably, there was a higher risk for both NCGC and CGC in H. pylori‐infected individuals. This population‐based cohort study provides valuable evidence supporting the association between current H. pylori infection and the risk of both NCGC and CGC. These findings contribute to the empirical basis for risk stratification and recommendations for UGI cancer screening.
- 19 December 2023
- Published by Springer Nature in Science China Life Sciences
- Vol. 67 (4) , 711-719
Cancer statistics for young adults aged 20 to 49 years in China from 2000 to 2017: a population-based registry study
An increasing cancer incidence among adults younger than 50 years has been reported for several types of cancer in multiple countries. We aimed to report cancer profiles and trends among young adults in China. Data from the China Cancer Registry Annual Report were used to estimate incidence and mortality among young adults (ages 20–49 years) in China in 2017, and an age-period-cohort model was employed to estimate the average annual percent change (AAPC) in incidence and mortality from 2000 to 2017. All 25 cancer types were grouped into obesity- or overweight-associated cancers (12 cancer types) and additional cancers (13 cancer types). In 2017, there were 681,178 new cases and 214,591 cancer deaths among young adults in China. Among young adults, the most common cancers were thyroid, breast, cervical, liver, lung, and colorectal cancer, and the leading causes of cancer deaths were liver, lung, cervical, stomach, breast, and colorectal cancer. From 2000 to 2017, the cancer incidence increased for all cancers combined among young adults, with the highest AAPC (1.46%) for adults aged 20–24 years, while cancer mortality decreased, with the highest AAPC (−1.63%) for those aged 35–39 years. In conclusion, the cancer incidence in China has increased among young adults, while cancer mortality has decreased for nearly all ages. Cancer control measures, such as obesity control and appropriate screening, may contribute to reducing the increasing cancer burden among young adults.
- 19 December 2023
- Published by Springer Nature in Science China Life Sciences
- Vol. 67 (4) , 711-719
Cancer statistics for young adults aged 20 to 49 years in China from 2000 to 2017: a population-based registry study
An increasing cancer incidence among adults younger than 50 years has been reported for several types of cancer in multiple countries. We aimed to report cancer profiles and trends among young adults in China. Data from the China Cancer Registry Annual Report were used to estimate incidence and mortality among young adults (ages 20–49 years) in China in 2017, and an age-period-cohort model was employed to estimate the average annual percent change (AAPC) in incidence and mortality from 2000 to 2017. All 25 cancer types were grouped into obesity- or overweight-associated cancers (12 cancer types) and additional cancers (13 cancer types). In 2017, there were 681,178 new cases and 214,591 cancer deaths among young adults in China. Among young adults, the most common cancers were thyroid, breast, cervical, liver, lung, and colorectal cancer, and the leading causes of cancer deaths were liver, lung, cervical, stomach, breast, and colorectal cancer. From 2000 to 2017, the cancer incidence increased for all cancers combined among young adults, with the highest AAPC (1.46%) for adults aged 20–24 years, while cancer mortality decreased, with the highest AAPC (−1.63%) for those aged 35–39 years. In conclusion, the cancer incidence in China has increased among young adults, while cancer mortality has decreased for nearly all ages. Cancer control measures, such as obesity control and appropriate screening, may contribute to reducing the increasing cancer burden among young adults.
- Open Access
- 22 September 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 64, 102243
Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)
- 22 September 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 64, 102243
Open AccessLandscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)
- Open Access
- 30 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102201
Long-term esophageal cancer risk and distinct surveillance intervals after a single endoscopy screening: a multicentre population-based cohort study
- 30 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102201
Open AccessLong-term esophageal cancer risk and distinct surveillance intervals after a single endoscopy screening: a multicentre population-based cohort study
- 7 August 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (9) , 1612-1622
Global patterns of cancer transitions: A modelling study
Cancer is a major contributor to global disease burden. Many countries experienced or are experiencing the transition that non‐infection‐related cancers replace infection‐related cancers. We aimed to characterise burden changes for major types of cancers and identify global transition patterns. We focused on 10 most common cancers worldwide and extracted age‐standardised incidence and mortality in 204 countries and territories from 1990 to 2019 through the Global Burden of Disease Study. Two‐stage modelling design was used. First, we applied growth mixture models (GMMs) to identify distinct trajectories for incidence and mortality of each cancer type. Next, we performed latent class analysis to detect cancer transition patterns based on the categorisation results from GMMs. Kruskal‐Wallis H tests were conducted to evaluate associations between transition patterns and socioeconomic indicators. Three distinct patterns were identified as unfavourable, intermediate and favourable stages. Trajectories of lung and breast cancers had the strongest association with transition patterns among men and women. The unfavourable stage was characterised by rapid increases in lung, breast and colorectal cancers alongside stable or decreasing burden of gastric, cervical, oesophageal and liver cancers. In contrast, the favourable stage exhibited rapid declines in most cancers. The unfavourable stage was associated with lower sociodemographic index, health expenditure, gross domestic product per capita and higher maternal mortality ratio (P < .001 for all associations). Our findings suggest that unfavourable, intermediate and favourable transition patterns exist. Countries and territories in the unfavourable stage tend to be socioeconomically disadvantaged, and tailored intervention strategies are needed in these resource‐limited settings.
- 7 August 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (9) , 1612-1622
Global patterns of cancer transitions: A modelling study
Cancer is a major contributor to global disease burden. Many countries experienced or are experiencing the transition that non‐infection‐related cancers replace infection‐related cancers. We aimed to characterise burden changes for major types of cancers and identify global transition patterns. We focused on 10 most common cancers worldwide and extracted age‐standardised incidence and mortality in 204 countries and territories from 1990 to 2019 through the Global Burden of Disease Study. Two‐stage modelling design was used. First, we applied growth mixture models (GMMs) to identify distinct trajectories for incidence and mortality of each cancer type. Next, we performed latent class analysis to detect cancer transition patterns based on the categorisation results from GMMs. Kruskal‐Wallis H tests were conducted to evaluate associations between transition patterns and socioeconomic indicators. Three distinct patterns were identified as unfavourable, intermediate and favourable stages. Trajectories of lung and breast cancers had the strongest association with transition patterns among men and women. The unfavourable stage was characterised by rapid increases in lung, breast and colorectal cancers alongside stable or decreasing burden of gastric, cervical, oesophageal and liver cancers. In contrast, the favourable stage exhibited rapid declines in most cancers. The unfavourable stage was associated with lower sociodemographic index, health expenditure, gross domestic product per capita and higher maternal mortality ratio (P < .001 for all associations). Our findings suggest that unfavourable, intermediate and favourable transition patterns exist. Countries and territories in the unfavourable stage tend to be socioeconomically disadvantaged, and tailored intervention strategies are needed in these resource‐limited settings.
- Open Access
- 3 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102138
Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study
- 3 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102138
Open AccessRacial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study